Regulation of Osteoclastogenesis by Mast Cell in Rheumatoid Arthritis

Kyoung-Woon Kim
OncoInsight Co.Ltd

Bo-Mi Kim
NEXEL

Ji-Yeon Won
OncoInsight Co.Ltd

Hong-Ki Min
Konkuk University School of Medicine

Kyung-Ann Lee
Soonchunhyang University College of Medicine

Sang-Heon Lee
Konkuk University School of Medicine

HAE-RIM KIM (kimhaerim@kuh.ac.kr)
Konkuk University School of Medicine  https://orcid.org/0000-0002-1911-6236

Research article

Keywords: rheumatoid arthritis, mast cell, osteoclast, cytokine

DOI: https://doi.org/10.21203/rs.3.rs-28824/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** We aimed to define the inflammatory and tissue-destructive roles of mast cells in rheumatoid arthritis (RA).

**Methods:** Serum and synovial fluid (SF) concentration levels of tryptase, chymase, and histamine were quantified using ELISA. After activating mast cells using IL-33, the production of TNF-a, IL-1b, IL-6, IL-17, RANKL, and MMPs was determined using real-time PCR and ELISA. Osteoclastogenesis was assessed in CD14+ monocytes from peripheral blood and SF, which were cultured with IL-33-activated mast cells, by counting TRAP-positive multinucleated cells.

**Results:** The concentration levels of serum tryptase, chymase, and histamine and SF histamine were higher in patients with RA than in controls. FceR1 and c-kit-positive mast cells were higher in RA synovium than in osteoarthritic (OA) synovium. Stimulation of mast cells by IL-33 increased the number of tryptase+chymase- and tryptase+chymase+ mast cells. IL-33 stimulation also increased the gene expression levels of TNF-a, IL-1b, IL-6, IL-17, RANKL, and MMP-9 in mast cells. Furthermore, IL-33 stimulated human CD14+ monocytes to differentiate into TRAP+ multinucleated osteoclasts. When CD14+ monocytes were co-cultured with mast cells, osteoclast differentiation was increased. Additionally, IL-33-activated mast cells stimulated osteoclast differentiation. The inhibition of intercellular contact between mast cells and monocytes using inserts reduced osteoclast differentiation.

**Conclusions:** IL-33 increased inflammatory and tissue destructive cytokines by activation of mast cells. Mast cells stimulated osteoclast differentiation in monocytes. Mast cells could stimulate osteoclastogenesis indirectly through production of tissue destructive cytokines and directly through stimulation of osteoclast precursors.

---

**Background**

Rheumatoid arthritis (RA) is characterized by intercellular interactions between macrophages, lymphocytes, synovial fibroblasts, osteoclasts, and chondrocytes, resulting in chronic inflammation and joint destruction [1]. Although the roles of most of these cells in RA pathogenesis are well-studied, mast cells and basophils remain important exceptions [2].

Mast cells, which are typically found in allergic diseases, are also found in RA synovial tissues and synovial fluid (SF). They are also known to be involved in RA pathogenesis. In RA, the synovium shows hyperplasia of mast cells, which can comprise up to 5% of all RA synovial cells. The number of mast cells in RA synovium is higher than that in osteoarthritic synovium [3]. Mast cells are mainly found around blood vessels, in the sublining area, and in areas of cartilage erosion. There are 2 types of mast cells: tryptase-positive MC_T cells and tryptase/chymase double-positive MC_Tc cells [3]. MC_Tc cells can be found in the normal synovium. The number of MC_T cells increases during early RA, indicating tissue inflammation, while that of MC_Tc cells increases during advanced RA, indicating tissue remodeling [4].
The role of mast cells in RA is unclear. Some reports have demonstrated pathogenic inflammatory roles of mast cells in RA, while others have shown anti-inflammatory roles of mast cells in RA. Four broad lines of argument have been made for claiming that mast cells have an inflammatory role in RA. First, the number of mast cells increases in RA synovium and this correlates with disease activity parameters [3]. Patients with active RA have more mast cells in synovial tissues than patients with end-stage RA [5]. Second, mast cells release various inflammatory cytokines in RA synovial joints, including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-8. Third, histamine and other mast cell mediators have a potential for angiogenesis, fibroblast and macrophage activation, osteoclast differentiation, and leukocyte recruitment [6-10]. In our previous study, histamine, a preformed mediator of activated mast cells, was found to stimulate the production of receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoclast differentiation via the histamine H4 receptor [10]. Fourth, mast cell-deficient animal models are resistant to arthritis [11-13]. In contrast to these arguments, there is also evidence for the anti-inflammatory role of mast cells in RA. First, mast cells suppress monocyte and fibroblast activation, dendritic cell migration, and Th1 differentiation by inducing the secretion of IL-10, IL-4, IL-13, and transforming growth factor (TGF)-β [8, 14-16]. Second, the development of arthritis in animal models is not affected by the deficiency of mast cells [17, 18]. Third, serum tryptase levels in RA patients are negatively correlated with the levels of C-reactive protein [19].

In this study, we aimed to assess the inflammatory and tissue-destructive roles of mast cells in RA. We quantified the serum and SF concentration of mast cell mediators such as tryptase, chymase, and histamine in RA patients and characterized mast cell phenotypes of the mononuclear cells in the SF of RA patients. We also determined the expression and production of proinflammatory cytokines, IL-17, matrix metalloproteinases (MMPs), and RANKL after stimulating mast cells with IL-33. Finally, we examined the effects of activated mast cells on osteoclast differentiation in human monocytes.

Methods

Ethics Statement and Patients

Written informed consent was obtained from healthy volunteers and patients with RA and osteoarthritis. All RA patients fulfilled the 2010 ACR/EULAR classification criteria for RA [20]. Serum was collected from 20 RA patients and 20 healthy volunteers. Clinical data of RA patients is as follows; 12 females and 8 males, age 60±16.8 years, rheumatoid factor (RF) 175.8±49.1 IU/L, anti-CCP antibody 462.2±163.2 IU/L, erythrocyte sedimentation rate (ESR) 59.6±7.2 mm/h, C-reactive protein (CRP) 4.5±1.0 mg/dl, DAS28-CRP 4.29±0.2, disease duration 2.8±1.7 years. Thirteen patients were not taking medications, and others were taking oral disease-modifying antirheumatic drugs (DMARDs). SF was collected from 20 RA patients and 20 patients with osteoarthritis of knee joints. All SF samples were obtained through therapeutic arthrocentesis before steroid injection into the swollen joints. Clinical data of RA patients is as follows; 12 females and 8 males, age 53.9±3.2 years, rheumatoid factor (RF) 143.5±39.3 IU/L, anti-CCP antibody 418.1±155.7 IU/L, ESR 51.5±7.8 mm/h, CRP 3.7±1.1 mg/dl, DAS28-CRP 3.8±1.1, disease duration 5.4±1.6 years. Two patients were not taking medications, 1 patient was taking tofacitinib, and
others were taking oral DMARDs. Synovial tissues were isolated from three RA patients (mean age 63.4 ± 4.6 years; range 38–76) and three osteoarthritis (OA) patients (mean age 63.5 ± 4.5 years; range 59-68) undergoing total knee-replacement surgery. Informed consent was obtained from all patients. All protocols were performed in accordance with relevant guidelines and regulations and were approved by the Institutional Review Board for Human Research in Konkuk University Hospital (KUH1010960).

Reagents

Recombinant IL-33, RANKL, and M-CSF were purchased from R&D systems (Minneapolis, MN).

Human mast cell line culture and stimulation

The human mast cell line (LUVA) was purchased from Kerafast (Kerafast, MA, USA) and maintained in StemPro-34 SFM at a concentration of 5×10^5 cells/ml. The cells were grown at 37 °C with 5% CO₂, and the medium was exchanged weekly with 50% fresh medium without exogenous cytokines. The mast cells were seeded in 6-well plates at a density of 5×10^4 cells/ml. After one day, the medium was replaced with StemPro-34 SFM culture medium with or without cytokines. The mast cells were then stimulated with 100 ng/mL human recombinant IL-33 (R&D Systems, Inc.) for 24 and 72 h. The supernatants and RNA were harvested and stored at −80 °C until analysis.

Enzyme-linked immunosorbent assay (ELISA)

SF and serum samples obtained from healthy volunteers and patients with RA and osteoarthritis were subjected to tryptase, chymase, and histamine analyses using tryptase (Boster Biological Technology, CA), chymase (Aviva Systems Biology, CA), and histamine (Enzo Life Sciences Inc., NY) ELISA kits, according to the manufacturers’ instructions. The levels of cytokines such as TNF-α, IL-1, IL-6, IL-17, RANKL, MMP-9, and MMP-13 in the culture supernatants from human mast cells were measured using sandwich ELISA (R&D Systems), according to the manufacturer’s instructions. Absorbance at 405 nm was also measured using an ELISA microplate reader (Molecular Devices, CA).

Flow cytometry

In the samples used for in vitro experiments, flow cytometry was performed after collecting the mast cells. Dead cells were excluded using the Fixable Viability Dye eFluor®506 (eBioscience). The cells were first stained with monoclonal antibodies. For surface staining, the cells were stained with mAbs against CD117 (c-kit)-APC (YB5.B8, IgG1k) (eBioscience, CA). The cells were then washed, fixed, permeabilized,
and stained with mAbs against FceRI alpha-PE-Cy7 (AER-37-CRA1, IgG2b) (eBioscience), tryptase-FITC (G3, IgG1k) (Santa Cruz Biotechnology, Inc, Texas), and chymase-PE (CC1, IgG1k) (Santa Cruz Biotechnology, Inc) to detect intracellular cytokines. Appropriate isotype controls were used for gate setting. Cells were analyzed using a FACSCalibur flow cytometer and FlowJo software.

Immunocytologic staining and confocal microscopy

To measure changes in protein expression, 4 μm-thick formalin-fixed and paraffin-embedded (FFPE) synovial sections were deparaffinized in xylene and rehydrated in ethanol and deionized water. Antigen retrieval was performed by heating these sections in a buffer solution (citrate buffer pH 6) (DAKO, Glostrup, Denmark) at 120 °C for 15 min. Slides were washed thrice (5 min each) with phosphate-buffered saline (PBS). The slides were then removed from PBS and each section was covered with 3% H2O2 solution (Sigma Aldrich, Saint Louis, Missouri (MO)) for 15 min at room temperature to block endogenous peroxidase activity. After washing, non-specific binding was blocked by incubation in 10% normal goat serum in PBS for 30 min at room temperature. The blocking buffer was then removed and the sections were incubated overnight with c-kit (CD117) polyclonal antibody (DAKO), FceR1 monoclonal antibody (Abcam, Cambridge, MA), FceR1 polyclonal antibody (LSBio, Seattle, WA), FITC-conjugated tryptase antibody (Santa Cruz, California), and chymase monoclonal antibody (MBL, Nagoya, Japan) at 4 °C. The sections were then washed and incubated with the secondary antibodies, anti-rabbit IgG Alexa Fluor 594 and anti-mouse IgG-APC (Invitrogen, Carlsbad, California), for 2 h at room temperature. The nuclei were also stained with DAPI (Invitrogen). The slides were then covered with a fluorescent mounting medium (DAKO) and the stained sections were visualized under a Zeiss microscope (LSM 510 Meta; Carl Zeiss, Oberkochen, Germany) at 200× and 400× magnifications. The area of target+ cell from RA and OA synovium was measured in using ImageJ software.

Real-time PCR for mRNA quantitation

mRNA was extracted from the samples using RNAzol B, according to the instructions of the manufacturer (Biotex, Friendswood, TX). The total mRNA (2 µg) was reverse transcribed at 42 °C using a SuperScript RT system (Takara). PCR was performed at a final volume of 20 ml in capillary tubes in a LightCycler (Roche Diagnostics). The reaction mixture contained 2 ml LightCycler FastStart DNA Master Mix for SYBR Green I (Roche Diagnostics), 0.5 mM of each primer, 4 mM MgCl2, and 2 ml of the template DNA. All the capillaries were amplified in a LightCycler with the following program: activation of polymerase at 95 °C for 10 min, followed by 45 cycles of 10 s at 95 °C and 10 s at 60 °C (beta-actin, IL-17, MMP-13) or 57 °C (TNF, IL-1b, IL-6, RANKL, MMP-9), and a final 10 s at 72 °C. The temperature transition rate was 20 °C/s for all steps. Melting curve analyses were performed immediately after amplification, using the following program: 0 s (hold time) at 95 °C, 15 s at 71 °C, and 0 s (hold time) at 95 °C. The rate of temperature change was 20 °C/s for all steps except the final step, during which it was 0.1 °C/s. The melting peaks
generated represented the quantity of each amplified product. The crossing point was defined as the maximum of the second derivative from the fluorescence curve. Negative controls, which contained all elements of the reaction mixture except for the template DNA, were also included. All samples were processed in duplicate.

**Isolation of peripheral blood (PB) monocytes and osteoclast differentiation**

PB mononuclear cells were separated, washed thrice with sterile PBS, and resuspended in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin-streptomycin (henceforth called complete medium). Freshly isolated PBMCs were incubated at 37 °C in the complete medium and allowed to adhere for 45 min. The non-adherent cells were removed, and the adherent cells were washed with sterile PBS, harvested with a rubber policeman, and stained with monocyte-specific anti-CD14 monoclonal antibodies to assess the purity of the preparation. Ninety percent of the isolated cells were monocytes expressing CD14. Osteoclast precursors were prepared using the monocyte-enriched fraction from PB. The cells were co-cultured for 3 weeks in minimal essential medium (MEM)-α with 10% heat-inactivated FBS in the presence of 25 ng/ml rhM-CSF and IL-33/IL-33-stimulated mast cells. The medium was changed on day 3 and then on alternate days thereafter. On day 21, tartrate-resistant acid phosphatase (TRAP)-positive cells were identified using a leukocyte acid phosphatase kit, according to the manufacturer's instructions (Sigma-Aldrich). The osteoclast precursors and mast cells/IL-33-stimulated mast cells were co-cultured in 24-well transwell plates separated by the membrane in lower and upper chambers, respectively (Costar, New York, NY). The medium was changed on day 3 and then every other day thereafter. On day 21, TRAP-positive cells were identified using a leukocyte acid phosphatase kit, according to the manufacturer's protocol (Sigma-Aldrich).

**Western blotting**

PB monocytes were incubated with or without IL-33 in the presence of RANKL. After incubation for 1 h, whole-cell lysates were prepared from approximately 1´10^7 cells by homogenization in the lysis buffer and then centrifuged at 14,000 rpm for 15 min. Protein concentration in the supernatant was determined using the Bradford method (Bio-Rad, Hercules, CA). Protein samples were separated using 10% SDS–PAGE and transferred onto a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). For western blotting, the membrane was pre-incubated with 0.5% skim milk in 0.1% Tween-20 and Tris-buffered saline (TTBS) at room temperature for 2 h. Primary antibodies against TRAF6, phospho-Src, Src, phospho-JNK, JNK, phospho-ERK, ERK, phospho-p38, p38, phospho-Akt, Akt, phospho-IkBa, IkBa, phospho-c-Jun, and c-Jun (Cell Signaling Technology Inc., Danvers, MA), diluted 1:1000 in 5% BSA-0.1% Tween-20/TBS, were added and incubated overnight at 4 °C. After washing the membrane 4 times with TTBS, horseradish peroxidase-conjugated secondary antibody was added and incubated for 1 h at room
temperature. After TTBS washing, hybridized bands were detected using the ECL detection kit and Hyperfilm-ECL reagents (Amersham Pharmacia).

**Statistical analysis**

All data are expressed as mean ± standard error of the mean (SEM). Statistical differences between two groups were assessed using Mann-Whitney U test and those between more than three groups were assessed using one-way analysis of variance (ANOVA) with Bonferroni’s multiple comparison post-hoc test. Differences with p<0.05 were considered statistically significant.

**Results**

**Serum and SF concentration levels of tryptase, chymase, and histamine in patients with RA**

The serum concentration levels of tryptase, chymase, and histamine were measured using ELISA in 20 patients with RA and 20 healthy controls. The clinical characteristics of the RA patients were as follows, age 60±16.8 years, rheumatoid factor (RF) 175.8±49.1 IU/L, anti-CCP antibody 462.2±163.2 IU/L, erythrocyte sedimentation range (ESR) 59.6±7.2 mm/h, C-reactive protein (CRP) 4.5±1.0 mg/dl, DAS28-CRP 4.29±0.2, disease duration 2.8±1.7 years. The serum concentration of tryptase was significantly higher (p = 0.002) in RA patients (4.04 ± 0.74 ng/ml) than in healthy controls (1.59 ± 0.14 ng/ml). The serum concentration of chymase was also significantly higher (p < 0.0001) in RA patients (82.77 ± 4.6 ng/ml) than in healthy controls (30.54 ± 1.58 ng/ml). Similarly, the serum concentration of histamine was also significantly higher (p = 0.048) in RA patients (4.33 ± 1.67 ng/ml) than in healthy controls (3.94 ± 0.54 ng/ml) (Fig. 1A). In RA patients, the serum concentration levels of chymase and histamine were correlated (r = 0.53, p = 0.025), as were those of chymase and tryptase (r = 0.59, p = 0.006). However, there was no correlation between the serum concentration levels of tryptase and histamine (r = 0.23, p = 0.37) (Fig. 1B).

The SF concentration of tryptase tended to be higher in RA patients (17.03 ± 3.73 ng/ml) than in patients with osteoarthritis (9.99 ± 0.97 ng/ml), although this difference was not statistically significant (p = 0.07). However, the SF concentration of histamine was significantly higher (p = 0.019) in RA patients (19.1 ± 5.33 ng/ml) than in patients with osteoarthritis (8.38 ± 1.65 ng/ml) (Fig. 1C). In RA patients, the SF concentration levels of chymase and histamine were not correlated (r = 0.6, p = 0.014). However, the SF concentration levels of chymase and histamine were not correlated (r = −0.15, p = 0.52), similar to those of chymase and tryptase (r = 0.27, p = 0.3) (Fig. 1D). The c-kit-, FceRI-, tryptase-, and chymase-positive cells in RA and OA synovial tissues were counted using multiple-fluorescence staining and confocal microscopy. C-kit, FceRI, and tryptase triple-positive cells were abundant in the RA synovium, but negligible in the OA synovium (Fig. 1E). By triple immunofluorescent labeling for c-kit, tryptase, and chymase, c-kit expression was found to consistently overlap with the expression of tryptase and chymase (Fig. 1F). FceRI expression also overlapped with the expression of tryptase and chymase (Fig. 1G).
Characterization of mast cells in RA SF

SFMCs were isolated from 6 patients with RA. We quantified c-kit-, FceRI-, tryptase-, and chymase-positive cells among these SFMCs. C-kit positive cells comprised 7.33 ± 1.81%, while FceRI-positive cells comprised 20.23 ± 5.42%, of the total SFMCs. C-kit and FceRI double-positive cells comprised 10.46 ± 3.26% of the total SFMC. Tryptase- and chymase-positive cells comprised 29.82 ± 8.06% and 29.45 ± 5.19% of total SFMC, respectively. Among c-kit and FceRI double-positive cells, there was no difference in the proportions of tryptase- and chymase-positive cells. Further, the characteristics of SFMCs from RA and osteoarthritis patients were not different (supplementary Fig. 1).

Stimulatory effects of IL-33 on mast cell lines (LUVA) phenotypes

IL-33 is major stimulatory cytokine for mast cell lines (LUVA). After stimulation with IL-33, we observed an increase in trypatase+chymase− and tryptase+chymase+ mast cells. Tryptase−chymase+ mast cells also increased after IL-33 stimulation, although this increase was not statistically significant (Fig. 2A, B). The gene expression levels of both tryptase and chymase in the mast cells also increased after IL-33 stimulation (Fig. 2C). We have added the gating strategy in the supplementary figure (supplementary Fig. 2).

Effects of IL-33 on the gene expression and production of proinflammatory and tissue-destructive cytokines in mast cell lines (LUVA).

When mast cells were stimulated by IL-33, the gene expression levels of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-17 increased (Fig. 3A). IL-33 stimulation also increased the production of TNF-α, IL-1β, and IL-17 in the culture media (Fig. 3B). IL-33 also affected bone and cartilage destruction by stimulating the gene expression and production of RANKL and MMP-9 in mast cells (Fig. 3C, D). However, IL-33 did not affect the production of MMP-13 (data not shown).

Effects of IL-33 on osteoclast differentiation in PB and SF monocytes

The effect of IL-33 on osteoclast differentiation depends on the type of osteoclast progenitors involved. IL-33 has anti-osteoclastogenic functions in human cord blood progenitors, mouse cell lines such as RAW264.7, and bone marrow cells. However, it stimulates osteoclast differentiation in human CD14+ monocytes [21-24]. Here, we attempted to define the effect of IL-33 on osteoclast differentiation in human PB CD14+ monocytes. IL-33 stimulated the differentiation of CD14+ monocytes to TRAP+ multinucleated osteoclasts in a dose-dependent manner. The gene expression levels of TRAP, NFATc1, DC-STAMP, OC-
STAMP, ATP6v0d2, and OSCAR in PB CD14+ monocytes increased upon IL-33 stimulation (Fig. 4A). Similar to PB monocytes, the gene expression levels of TRAP, NFATc1, DC-STAMP, OC-STAMP, ATP6v0d2, and OSCAR also increased in SF monocytes upon IL-33 stimulation (Fig. 4B).

**Effects of IL-33 on RANKL-induced osteoclast differentiation in PB and SF monocytes**

RANKL is a major stimulant for the differentiation of mature osteoclasts. When we cultured PB monocytes with RANKL and M-CSF, TRAP+ multinucleated osteoclasts were differentiated. However, IL-33 reduced this RANKL-induced osteoclast differentiation. The gene expression levels of TRAP, NFATc1, cathepsin-K, ATP6v0d2, and OSCAR in PB monocytes were increased upon RANKL stimulation, but decreased after the addition of IL-33 (Fig. 5A). Further, RANKL and IL-33 treatment had similar effects on osteoclast differentiation in SF monocytes as on PB monocytes (Fig. 5B).

As described in the previous sections, although IL-33 stimulated osteoclastogenesis, when IL-33 was added in the culture system with RANKL, osteoclastogenesis was reduced. To determine the change in intracellular signaling caused by IL-33 in RANKL-induced osteoclastogenesis, PB monocytes were cultured with or without IL-33 in the presence of RANKL. IL-33 decreased RANKL-induced phosphorylation of Src, ERK, p38 MAPK, IkBa, and c-jun. However, the expression of TRAF6 and the phosphorylation of JNK and Akt were not affected by IL-33 (Fig. 5C).

**Effects of mast cells on osteoclast differentiation in PB monocytes**

Co-culturing PB CD14+ monocytes with mast cells increased osteoclast differentiation regardless of the activation of mast cells. However, IL-33-activated mast cells stimulated more osteoclast differentiation. To determine the osteoclastogenic effect of monocyte-mast cell contact, transwell inserts were placed between monocytes and mast cells in the co-culture system. When intercellular contact was inhibited by the transwell insert, osteoclast differentiation decreased (Fig. 6A). When SF monocytes were co-cultured with mast cells, IL-33-activated mast cells induced more osteoclast differentiation than non-activated mast cells. However, the transwell inserts reduced osteoclast differentiation by IL-33-activated mast cells (Fig. 6B). When RANKL was added in the co-culture system, osteoclast differentiation was induced, regardless of co-culture with mast cells. The osteoclastogenic effect of IL-33-activated mast cells was not different from that of non-activated mast cells. However, the transwell inserts again reduced osteoclast differentiation in both activated and non-activated mast cells (Fig. 6C). The effect of transwell inserts on osteoclast differentiation in the presence of RANKL was similar in SF and PB monocytes (Fig. 6D).

**Discussion**

Mast cells have so far not been a major focus of RA research; results from in vitro cellular experiments and in vivo animal studies have been inconsistent. Synovial mast cells have been shown to be
associated with inflammation, autoantibody production, and high disease activity in early RA [25]. In this study, we investigated the role of mast cells in bone destruction during RA.

We quantified the serum and SF concentration levels of mast cell mediators, including tryptase, chymase, and histamine. The serum concentration levels of all three were higher in RA patients than in patients with osteoarthritis. Further, the concentration of chymase was correlated with that of tryptase and histamine. Although their concentration levels were higher in SF than in serum samples, only histamine was significantly higher in RA than in osteoarthritis. Among the important mast cell mediators, tryptase has been shown to be of clinical and experimental significance in RA. Serum tryptase is correlated with RA disease activity indices, and anti-tryptase antibodies have been detected in RA synovial tissues and sera. Further, tryptase inhibits apoptosis in RA synovial fibroblasts, while tryptase inhibition reduces inflammatory parameters in animal models of arthritis [26-28]. In contrast, the clinical and pathological roles of chymase in RA remain unclear. As for histamine, its production has been shown to be increased in RA, although histamine levels do not reflect clinical disease activity [10, 29].

Previous studies have shown that the number of mast cells increases in RA synovial tissue, especially in early RA [25, 30]. However, the proportion of mast cells in the SF has not been investigated so far. We found that c-kit and FceR1 double-positive mast cells comprised over 10% of SFMCs in RA patients, suggesting that a considerable number of mast cells exists in the SF, which may play a major role in inflammation and tissue destruction. We also characterized synovial mast cells using confocal staining and flow cytometric analyses. Compared with osteoarthritic synovial tissues, RA synovial tissues had more c-kit- and FceR1-positive mast cells, which produced both tryptase and chymase. Tryptase and chymase are markers for mast cell activation, and as mast cells in the RA synovium had both tryptase and chymase, it is likely that these mast cells are activated.

Mast cells are activated upon stimulation by cytokines such as IL-3, IL-4, IL-5, and IL-33, immune complexes, toll-like receptor-2 and 4, Fcg receptors, and direct interaction with helper T-cells [31-34]. IL-33, a member of the IL-1 family, which is expressed in epithelial cells, fibroblasts, dendritic cells, and macrophages [35], is also associated with RA. Its level is increased in the serum and SF of RA patients and decreases with RA treatment [35]. IL-33 stimulates mast cells to produce TNF and IL-6, two major proinflammatory cytokines, in RA [36].

Here, we used IL-33 to activate mast cells, and analyzed subsequent changes in mast cell phenotype and expression of proinflammatory cytokines and tissue-degrading molecules such as RANKL and MMPs. IL-33 stimulation increased the number of tryptase-positive and tryptase/chymase-positive mast cells, suggesting that IL-33 was effective in stimulating mast cells and that tryptase is the best marker for mast cell activation. A previous study showed that synovial fibroblast-derived IL-33 promotes the expression of tryptase in mast cells [37], indicating that synovial fibroblasts may be a major source of IL-33 for the activation of mast cells in the RA synovium. IL-33 also increased the expression of TNF-a, IL-1b, IL-6, and IL-17, suggesting that activated mast cells may be a major source of proinflammatory cytokines in the RA synovium. Moreover, IL-33 stimulated the expression of RANKL and MMP-9, which are associated with
bone and cartilage destruction in RA. This result also suggests that activated mast cells may have joint tissue-destructive roles in RA. Although RANKL is crucial for osteoclast differentiation, osteoclastogenesis occurs in the joints of RA patients without RANKL. Instead, TNF-a, IL-1b, and Th17 cytokines induce osteoclast differentiation from their precursors [38-40]. The stimulatory effect of IL-33 on RANKL production in monocytes suggests that IL-33 could have a bone-destructive role in RA.

IL-33 induces osteoclast differentiation in human PB and SF monocytes through its receptor ST2 and has a synergistic effect on osteoclast differentiation with RANKL [23, 41]. However, IL-33 has a double-sided effect on osteoclast differentiation, and this is not yet well defined. We studied the role of IL-33 on osteoclast differentiation in three different osteoclast culture systems. In addition to PB monocytes, we also used SF monocytes from RA patients as osteoclast precursors. First, we stimulated osteoclast precursors with IL-33 in the absence of RANKL. IL-33 induced osteoclast differentiation in both PB and SF monocytes, indicating the osteoclastic effect of IL-33 independent of RANKL stimulation. This result is consistent with those of a previous study on human CD14+ monocytes [23]. Second, we added IL-33 in the osteoclast culture systems in the presence of RANKL and found that IL-33 reduced RANKL-induced osteoclastogenesis. This result is in contrast to the findings from the previous study [23]. We also found that the phosphorylation of signal molecules plays a crucial role in RANKL-induced osteoclastogenesis. IL-33 inhibited the phosphorylation of src, ERK, p38, NF-kB, and c-jun. Thus, IL-33 stimulated osteoclastogenesis, but reduced the osteoclastogenic effect of RANKL. Future studies should aim to explore the underlying mechanisms of the inhibitory effect of IL-33 on RANKL-induced osteoclastogenesis in more detail.

Finally, we investigated the effect of intercellular contact between mast cells and osteoclast precursors. Co-culturing mast cells with osteoclast precursors increased osteoclast differentiation. IL-33-stimulated mast cells induced more osteoclast differentiation than non-activated mast cells. To determine the effect of intercellular contact between mast cells and osteoclast precursors, we inhibited their contact using transwell inserts. The inhibition of cellular contact decreased osteoclast differentiation, suggesting that cell-cell contact is the major mechanism of mast cell-induced osteoclast differentiation, rather than cytokine stimulation. The addition of RANKL to the culture system masked the effects of IL-33-activated mast cells, indicating that RANKL has a stronger osteoclastogenic effect than IL-33. However, the inhibition of contact between mast cells and osteoclast precursors diminished the osteoclastogenic effect of RANKL.

Conclusions

Mast cells and their mediators such as tryptase, chymase, and histamine were increased in the synovial tissues and SF of RA patients, compared to healthy controls and osteoarthritis patients. Mast cells stimulated osteoclast differentiation through intercellular contact. The inhibition of mast cells could therefore be a promising new therapeutic strategy for the prevention of joint destruction in RA.

Abbreviations
RA, rheumatoid arthritis; OA, osteoarthritis; SF, synovial fluid; MC, Mast cells; TNF, tumor necrosis factor; IL, interleukin; RANKL, receptor activator of nuclear factor κB ligand; MMPs, Matrix metallopeptidases; TGF, transforming growth factor; CD, cluster of differentiation; TRAP, tartrate-resistant acid phosphatase; PBMC, Peripheral blood mononuclear cell; ELISA, Enzyme-linked immunosorbent assay; PCR, polymerase chain reaction; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide electrophoresis; SEM, standard error mean; Th, helper T cell; TTBS, Tween 20 in Tris-buffered saline

**Declarations**

**Acknowledgments**

Not applicable

**Funding**

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (NRF-2018R1D1A1A02050982) and the Ministry of Science, ICT and Future Planning (NRF-2018R1A2B2006820).

**Availability of data and materials**

The datasets generated and/or analyzed in this study are available from the corresponding author upon reasonable request.

**Authors’ contributions**

K.W. Kim and H.R. Kim conceptualized the project; B.M. Kim, J.Y. Won and H. K. Min designed the methodology; K. A. Lee and S. H. Lee conducted the investigation; K.W. Kim and H.R. Kim wrote the original draft; K.W. Kim, B.M. Kim, J.Y. Won, H. K. Min, K. A. Lee, S. H. Lee and H.R. Kim reviewed and edited the writing; K.W. Kim and H.R. Kim acquired funding; K.W. Kim and H.R. Kim located resources; and H.R. Kim supervised the study.

**Ethics approval and consent to participate**

This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board for Human Research, Konkuk University Hospital (KUH1010186).
Consent for publication

Informed consent was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

References

1. Angelotti F, Parma A, Cafaro G, Capecchi R, Alunno A, Puxeddu I: One year in review 2017: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 2017, 35(3):368-378.

2. Rivellese F, Nerviani A, Rossi FW, Marone G, Matucci-Cerinic M, de Paulis A, Pitzalis C: Mast cells in rheumatoid arthritis: friends or foes? Autoimmun Rev 2017, 16(6):557-563.

3. Gotis-Graham I, McNeil HP: Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 1997, 40(3):479-489.

4. Maruotti N, Crivellato E, Cantatore FP, Vacca A, Ribatti D: Mast cells in rheumatoid arthritis. Clin Rheumatol 2007, 26(1):1-4.

5. Godfrey HP, Ilardi C, Engber W, Graziano FM: Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 1984, 27(8):852-856.

6. Triggiani M, Gentile M, Secondo A, Granata F, Oriente A, Tagliatela M, Annunziato L, Marone G: Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001, 166(6):4083-4091.

7. Taylor DJ, Yoffe JR, Brown DM, Woolley DE: Histamine stimulates prostaglandin E production by rheumatoid synovial cells and human articular chondrocytes in culture. Arthritis Rheum 1986, 29(2):160-165.

8. Bury TB, Corhay JL, Radermecker MF: Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy 1992, 47(6):624-629.

9. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y: Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007, 41(2):165-174.

10. Kim KW, Kim BM, Lee KA, Lee SH, Firestein GS, Kim HR: Histamine and Histamine H4 Receptor Promotes Osteoclastogenesis in Rheumatoid Arthritis. Sci Rep 2017, 7(1):1197.

11. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297(5587):1689-1692.

12. Schubert N, Dudeck J, Liu P, Karutz A, Speier S, Maurer M, Tuckermann J, Dudeck A: Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced
arthriti in which T cells are bypassed. *Arthritis Rheumatol* 2015, 67(4):903-913.

13. van der Velden D, Lagrauw HM, Wezel A, Launay P, Kuiper J, Huizinga TW, Toes RE, Bot I, Stoop JN: Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. *Arthritis Res Ther* 2016, 18(1):138.

14. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL: Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. *J Immunol* 1998, 161(5):2586-2593.

15. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K et al: Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. *Nature* 2001, 413(6854):420-425.

16. Jovanovic D, Pelletier JP, Alaaeddine N, Mineau F, Geng C, Ranger P, Martel-Pelletier J: Effect of IL-13 on cytokines, cytokine receptors and inhibitors on human osteoarthritis synovium and synovial fibroblasts. *Osteoarthritis Cartilage* 1998, 6(1):40-49.

17. Pitman N, Asquith DL, Murphy G, Liew FY, Mclnnes IB: Collagen-induced arthritis is not impaired in mast cell-deficient mice. *Ann Rheum Dis* 2011, 70(6):1170-1171.

18. Zhou JS, Xing W, Friend DS, Austen KF, Katz HR: Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. *J Exp Med* 2007, 204(12):2797-2802.

19. Rossini M, Viapiana O, Zanoni G, Tripi G, Idolazzi L, Fracassi E, Adami G, Adami S, Gatti D: Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al. *Arthritis Rheumatol* 2016, 68(3):769.

20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD et al: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010, 62(9):2569-2581.

21. Kiyomiya H, Ariyoshi W, Okinaga T, Kaneuji T, Mitsugi S, Sakurai T, Habu M, Yoshioka I, Tominaga K, Nishihara T: IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression. *Biochem Biophys Res Commun* 2015, 460(2):320-326.

22. Zaiss MM, Kurowska-Stolarska M, Bohm C, Gary R, Scholtysek C, Stolarski B, Reilly J, Kerr S, Millar NL, Kamradt T et al: IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. *J Immunol* 2011, 186(11):6097-6105.

23. Mun SH, Ko NY, Kim HS, Kim JW, Kim DK, Kim AR, Lee SH, Kim YG, Lee CK, Lee SH et al: Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. *Cell Mol Life Sci* 2010, 67(22):3883-3892.

24. Eeles DG, Hodge JM, Singh PP, Schuijers JA, Grills BL, Gillespie MT, Myers DE, Quinn JM: Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor. *Mol Cell Endocrinol* 2015, 399:259-266.
25. Rivellese F, Mauro D, Nerviani A, Pagani S, Fossati-Jimack L, Messemaker T, Kurreeman FAS, Toes REM, Ramming A, Rauber S et al: Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. *Ann Rheum Dis* 2018, 77(12):1773-1781.

26. Guo Y, Wu Q, Ni B, Mou Z, Jiang Q, Cao Y, Dong H, Wu Y: Tryptase is a candidate autoantigen in rheumatoid arthritis. *Immunology* 2014, 142(1):67-77.

27. Denadai-Souza A, Ribeiro CM, Rolland C, Thouard A, Deraison C, Scavone C, Gonzalez-Dunia D, Vergnolle N, Avellar MCW: Effect of tryptase inhibition on joint inflammation: a pharmacological and lentivirus-mediated gene transfer study. *Arthritis Res Ther* 2017, 19(1):124.

28. Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y: Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. *Arthritis Rheum* 2010, 62(4):952-959.

29. Guo Y, Cao Y, Wu Q, Ni B, Mou Z, Jiang Q, Dong H, Wu Y: Tryptase is a candidate autoantigen in rheumatoid arthritis. *Immunology* 2014, 142(1):67-77.

30. Rivellese F, Rossi FW, Galdiero MR, Pitzalis C, de Paulis A: Mast Cells in Early Rheumatoid Arthritis. *Int J Mol Sci* 2019, 20(8).

31. Suurmond J, Rivellese F, Dorjee AL, Bakker AM, Rombouts YJ, Rispens T, Wolbink G, Zaldumbide A, Hoeben RC, Huizinga TW et al: Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. *Ann Rheum Dis* 2015, 74(10):1915-1923.

32. Rivellese F, Suurmond J, Habets K, Dorjee AL, Ramamoorthi N, Townsend MJ, de Paulis A, Marone G, Huizinga TW, Pitzalis C et al: Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses. *Arthritis Rheumatol* 2015, 67(9):2343-2353.

33. Lee H, Kashiwakura J, Matsuda A, Watanabe Y, Sakamoto-Sasaki T, Matsumoto K, Hashimoto N, Saito S, Ohmori K, Nagaoka M et al: Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through Fcgamma receptor I and Fcgamma receptor II. *Arthritis Rheum* 2013, 65(1):109-119.

34. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB et al: IL-33 exacerbates antigen-induced arthritis by activating mast cells. *Proc Natl Acad Sci U S A* 2008, 105(31):10913-10918.

35. Xu WD, Zhang M, Zhang YJ, Ye DQ: IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy. *Hum Immunol* 2013, 74(9):1057-1060.

36. Yuan FL, Li X, Lu WG, Li CW, Xu RS, Dong J: IL-33: a promising therapeutic target for rheumatoid arthritis? *Expert Opin Ther Targets* 2011, 15(5):529-534.

37. Kaieda S, Shin K, Nigrovic PA, Seki K, Lee RT, Stevens RL, Lee DM: Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). *J Biol Chem* 2010, 285(28):21478-21486.

38. Amarasekara DS, Yun H, Kim S, Lee N, Kim H, Rho J: Regulation of Osteoclast Differentiation by Cytokine Networks. *Immune Netw* 2018, 18(1):e8.
39. Kim KW, Kim HR, Kim BM, Cho ML, Lee SH: **Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis.** *Am J Pathol* 2015, **185**(11):3011-3024.

40. Kim HR, Kim KW, Kim BM, Lee KA, Lee SH: **N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis.** *Korean J Intern Med* 2019, **34**(1):210-219.

41. Lee EJ, So MW, Hong S, Kim YG, Yoo B, Lee CK: **Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis.** *Cytokine* 2016, **77**:35-43.

**Figures**
Figure 2

Effect of IL-33 on the expression of tryptase and chymase in mast cells. (A) Human mast cells were culture with 100 ng/ml of IL-33 for 24 h, after which c-kit+ FcERI+ cells were gated for further analysis. (B) Percentages of tryptase- and chymase-positive mast cells were measured by flow cytometry. (C) Gene expression levels of tryptase and chymase were measured using real-time PCR. Data were normalized to
the expression level of beta-actin and reported in relative expression units. Data are presented as mean ± SEM from four independent experiments. *, p<0.05 and **, p<0.01.

**Figure 3**

Gene expression levels and production of proinflammatory cytokines and tissue-destructive molecules in mast cells stimulated by IL-33. (A) After mast cells were cultured with 100 ng/ml of IL-33, the gene expression levels of TNF-a, IL-1a, IL-6, and IL-17 were determined by real-time PCR. (B) Production of TNF-a, IL-1B, IL-6, and IL-17 in the culture media was quantified using ELISA. (C) After mast cells were cultured with 100 ng/ml of IL-33 for 24 h, the gene expression levels of RANKL and MMP-9 were determined by real-time PCR. (D) Production of RANKL and MMP-9 in the culture media was quantified using ELISA. Data from real-time PCR analyses were normalized to the expression level of beta-actin and reported in relative expression units. Data are presented as mean ± SEM from six independent experiments. *, p<0.05, **, p<0.01, and ***, p<0.001
Figure 4

Effect of IL-33 on osteoclast differentiation in peripheral blood (PB) and synovial fluid (SF) monocytes. (A) PB and (B) SF CD14+ monocytes were cultured with various doses of IL-33 along with 25 ng/ml M-CSF. After 21 days of culturing, TRAP-positive multinucleated cells, mature osteoclasts, were counted. Figures represent data from one of three independent experiments, and the bars represent mean ± SEM. Gene expression levels of osteoclast markers such as TRAP, NFATc1, DC-STAMP, OC-STAMP, and ATP6v0d2 were measured using real-time PCR. Data were normalized to the expression level of beta-actin and reported in relative expression units. *, p<0.05, **, p<0.01, and ***, p<0.001
Figure 6

Effects of mast cells on osteoclast differentiation in peripheral blood (PB) and synovial fluid (SF) monocytes. (A) PB and (B) SF CD14+ monocytes were co-cultured with mast cells or IL-33-simulated mast cells in the presence of M-CSF for 21 days, after which TRAP-positive multinucleated cells, mature osteoclasts, were counted. To determine the effect of cell-cell contact, transwell inserts were placed between the mast cells and the monocytes. (C) PB and (D) SF CD14+ monocytes were co-cultured with...
mast cells or IL-33-simulated mast cells in the presence of M-CSF and RANKL for 21 days, after which TRAP-positive multinucleated cells, mature osteoclasts, were counted. Figures represent one of 3 independent experiments, and the bars represent mean ± SEM. *, p<0.05, **, p<0.01, and ***, p<0.001 indicate significant difference from the value for nil condition, while #, p<0.05, ##, p<0.01, and ###, p<0.001 indicate significant difference between two conditions.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile2Supplementaryfigure2.tif